| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BCRX | Common Stock | Award | $0 | +6,820 | +13% | $0.000000 | 59,550 | 12 Jun 2024 | Direct | F1 |
| transaction | BCRX | Common Stock | Sale | $40,925 | -6,698 | -11% | $6.11 | 52,852 | 14 Jun 2024 | Direct | F2, F3 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BCRX | Automatic Stock Option Grant | Award | $0 | +49,933 | $0.000000 | 49,933 | 12 Jun 2024 | Common Stock | 49,933 | $6.30 | Direct | F4 |
| Id | Content |
|---|---|
| F1 | Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. |
| F2 | These shares were sold with the sole purpose of generating sufficient proceeds to cover the tax liability incurred in connection with the vesting of 16,745 Restricted Stock Units on June 13, 2024. |
| F3 | The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.08 to $6.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |
| F4 | Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. |